| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19NCT04678830 | CytoDyn, Inc. | Phase 2 | Completed | 2021-06-05Actual |
| A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRSNCT04681066 | CALC | Phase 2 | Completed | 2024-05-15Actual |
| CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCNCT04681131 | BioAtla, Inc. | Phase 2 | Completed | 2025-07-09Actual |
| HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)NCT04684914 | ALT | Phase 2 | Terminated | 2024-03-27Actual |
| A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 TrialNCT04685993 | LPCN | Phase 2 | Completed | 2022-03-01Actual |
| A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)NCT04688164 | RLMD | Phase 3 | Completed | 2022-11-01Actual |
| A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT04688931 | URGN | Phase 3 | Terminated | 2023-03-17Actual |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04691570 | ANNX | Phase 2 | Completed | 2023-01-17Actual |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With IchthyosisNCT04697056 | Vanda Pharmaceuticals | Phase 2 | Terminated | 2021-11-19Actual |
| A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform RashNCT04697069 | Vanda Pharmaceuticals | Phase 2 | Terminated | 2021-12-13Actual |
| Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)NCT04697810 | Can-Fite BioPharma | Phase 2 | Unknown | 2025-04-15Estimated |
| A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)NCT04700280 | LKFT | Phase 2 | Terminated | 2021-10-28Actual |
| Efficacy and Safety of ANX005 in Subjects With Guillain-Barré SyndromeNCT04701164 | ANNX | Phase 3 | Completed | 2024-04-20Actual |
| A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT04702568 | BioCryst Pharmaceuticals | Phase 2 | Terminated | 2023-10-04Actual |
| Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory FailureNCT04705597 | BIOA | Phase 2 | Terminated | 2022-04-20Actual |
| Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO DeficiencyNCT04706013 | Medicure | Phase 3 | Active not recruiting | 2027-09Estimated |
| Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsNCT04707768 | Akebia Therapeutics | Phase 3 | Completed | 2023-01-06Actual |
| A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)NCT04710576 | Syndax Pharmaceuticals | Phase 2 | Recruiting | 2023-04-07Actual |
| A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood PressureNCT04714320 | IONS | Phase 2 | Completed | 2022-06-29Actual |
| Atacicept in Subjects With IgA NephropathyNCT04716231 | VERA | Phase 3 | Active not recruiting | 2025-05-15Actual |
| A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)NCT04718961 | MIRM | Phase 2 | Terminated | 2022-12-07Actual |
| Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaNCT04720534 | Arrowhead Pharmaceuticals | Phase 2 | Completed | 2023-03-09Actual |
| Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 DiseaseNCT04723537 | RedHill Biopharma Limited | Phase 2, Phase 3 | Terminated | 2021-12-28Actual |
| Open-Label Study of Setmelanotide in Hypothalamic ObesityNCT04725240 | RYTM | Phase 2 | Completed | 2022-06-28Actual |
| Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021NCT04728347 | Arcturus Therapeutics, Inc. | Phase 2 | Terminated | 2021-12-28Actual |
| A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)NCT04728711 | ALDX | Phase 2 | Completed | 2022-01-18Actual |
| A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).NCT04729751 | MIRM | Phase 2 | Completed | 2024-12-17Actual |
| A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseNCT04735393 | ALDX | Phase 3 | Completed | 2022-10-11Actual |
| Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGNCT04735536 | Cognition Therapeutics | Phase 2 | Completed | 2023-04-26Actual |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173 | RCUS | Phase 2 | Completed | 2026-09-17Actual |
Trial details
- Registry ID
- NCT04678830
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04681066
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04681131
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04684914
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04685993
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04688164
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04688931
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04691570
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04697056
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04697069
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04697810
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04700280
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04701164
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04702568
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04705597
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04706013
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04707768
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04710576
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04714320
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04716231
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04718961
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04720534
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04723537
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04725240
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04728347
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04728711
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04729751
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04735393
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04735536
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04736173
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.